CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biotoscana Investments SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biotoscana Investments SA
70, Route d'Esch
LUXEMBOURG, 1470  Luxembourg Ticker: GBIO33GBIO33

This company was Merged or Acquired on 11/29/2019.
This is a Subsidiary, click here for the Parent Company

Business Summary
Biotoscana Investments SA is a Luxembourg-based company engaged in the healthcare industry. The Company develops, manufactures and distributes pharmaceutical products. The Company offers drugs for the treatment of infectious and rare diseases, oncology, onco-hematology, special treatments and immunology, among others. Its product development pipeline is divided into two business models: partnership product development, which is focused on building relationships to license and commercialize products that are new to Latin America, and internal product development, which is focused on studying, designing, formulating and manufacturing branded generic products. Apart from the Luxembourg, the Company operates worldwide in a number of countries, including Peru, Argentina and Ecuador, among others.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201912/31/2018Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Business Names
Business Name
BIO
GBIO33
Laboratorio DOSA

General Information
Number of Employees: 679 (As of 6/30/2019)
Outstanding Shares: 105,957,911 (As of 6/30/2019)
Stock Exchange: SAO


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019